News

AACL is a provider of analytical testing and research services to companies that develops, produces and distributes nutritional supplements, nutraceuticals, pharmaceuticals and biopharmaceuticals. AACL offers clients to evaluate

The primary objective of the study is to establish the maximum tolerated dose of daily oral BMN 673. However, the secondary objectives are to evaluate the safety, tolerability,

In addition to receiving an upfront payment of $1m, which includes $500,000 in cash and $500,000 in equity shares at a 50% premium investment, Dyax is eligible for

The analysed drugs include Pfizer’s Celebrex, Merck’s Vioxx, Novartis’s Prexige, the experimental etoricoxib, ibuprofen, and diclofenac. Naproxen and Ibuprofen (sold as Advil) were found to be the least

Amgen plans to simultaneously develop three oncology drugs, the most advanced of them being Motesanib, which is being developed in collaboration with the Tokyo-based Takeda Pharmaceutical. Referring to

The milestone payment will also be used to start a Phase 1 clinical trial of a HuCAL-derived, fully human antibody to treat inflammatory diseases. MorphoSys chief scientific officer

Cravit IV, administered once daily, is classified as a respiratory quinolone suited to treat respiratory tract infections. Daiichi said that 100mg Cravit tablets were approved in Japan for

The company expects to initiate a Phase 1/2 clinical trial to investigate the safety and efficacy of the drug, in 2011. ISV-101 combines a low dose of the

Amarin has two final-stage human tests of its advanced experimental cholesterol drug AMR101. Bloomberg.com has quoted San Francisco-based Wedbush Securities analyst Duane Nash as saying that the cholesterol